CMND logo

CLEARMIND MEDICINE INC

CMNDNASDAQ
🏆 #5408 by market capUS Equity
$258.30▲ $15.50 (+6.00%)
Simulated price
🔔
Track CMND
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 6.0%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
76
Good
No chart data available for CMND.

Trading Snapshot

Day Range
$256.88 – $261.01
52-Week Range
$0.77 – $480.00
Volume
$3.30B
Avg Volume
$3.08B
Shares Outstanding
1.5M
Next Earnings
Oct 31, 2026

Fundamentals Snapshot

Annual Revenue
$440,218
Last Q Revenue
$122,422
P/E Ratio
-0.1
P/S Ratio
0.0x
EPS (TTM)
$-4.74
Dividend Yield
0.00%
Dilution (1yr)
+35.5%

Why Investors Own CMND

  • ✓High-growth profile — revenue up +7.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 63% gross margin and 17% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CMND logo

CLEARMIND MEDICINE INC

CMND
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$6M▼ −1.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5M▼ −30.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.4M▲ +35.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1M▼ −$8M YoY
StockOtter · stockotter.space

About CLEARMIND MEDICINE INC

Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$333.77
▲ +29.2% Upside
High Target$397.96
Low Target$304.83
Based on 9 analysts

Latest News & Updates

🚀
Barron’s·2h ago

CLEARMIND MEDICINE INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift CMND price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

CLEARMIND MEDICINE INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.